Alvotech reported first-half 2026 revenue of $212 million, down from $306 million a year earlier, as manufacturing slowed during facility and quality-system improvements at its Reykjavik site. Adjusted EBITDA was $47 million for the first six months, compared with $54 million in the prior-year period, while gross margin was 54%, versus 55% a year earlier. Management said production returned to planned levels near the end of the second quarter and reaffirmed full-year guidance of $650 million to $700 million in revenue and $180 million to $220 million in adjusted EBITDA. The company strengthened liquidity through a $165 million equity offering and a term loan facility of up to $75 million, providing approximately $240 million in new capital for manufacturing, pipeline investment and commercialization. The FDA closed its Reykjavik inspection with a Voluntary Action Indicated classification, and reviews are underway for biosimilar applications targeting Simponi Aria, EYLEA and Prolia/Xgeva, with potential U.S. approvals expected in the fourth quarter of 2026.
AlvotechReaffirmed guidance and raised $240M in new capital despite revenue decline
Teva Pharma Industries Ltd ADR
